Ken Kent

Title: Ken Kent: Innovator in Oligonucleotide Technology

Introduction

Ken Kent is a notable inventor based in Mountain View, CA (US). He has made significant contributions to the field of oligonucleotide technology, holding 2 patents that focus on innovative methods for cell membrane permeation.

Latest Patents

Ken Kent's latest patents include groundbreaking work on oligonucleotides and their analogs capable of passive cell membrane diffusion. These oligonucleotides are designed to contain at least two nucleotide residues and exhibit a log distribution coefficient in octanol:water ranging from about 0.0 to 2.5. Additionally, they demonstrate a solubility in water of at least 0.001 µg/mL. In preferred embodiments, either at least 80% of the internucleotide linkages are non-ionic, or at least 80% of the bases contain lipophilic hydrocarbyl substitutions, or a combination of these sums to 80%. These innovative oligonucleotides can be conjugated to labels for visualizing cells, enhancing their utility in biological research.

Career Highlights

Ken Kent is currently associated with Gilead Sciences, Inc., where he continues to advance his research in oligonucleotide technology. His work has positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Throughout his career, Ken has collaborated with esteemed colleagues such as Norbert W. Bischofberger and Rick Wagner. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Ken Kent's contributions to oligonucleotide technology are paving the way for new advancements in cell biology and therapeutic applications. His innovative patents and collaborations highlight his commitment to scientific progress and the betterment of healthcare solutions.